Krystal Biotech, Inc.
About Krystal Biotech, Inc.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $389.1M
- Net income
- $204.8M
- Total assets
- $1.3B
- Market cap
- $8.9B
- Operating margin
- 41.5%
- Net margin
- 52.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $389.1M
- Operating expenses
- $227.8M
- Operating income
- $161.3M
- Income tax
- -$15.4M
- Net income
- $204.8M
- EPS (basic)
- $7.08
- EPS (diluted)
- $6.84
Balance sheet
- Total assets
- $1.3B
- Current assets
- $1.0B
- Total liabilities
- $114.2M
- Current liabilities
- $102.9M
- Shareholders’ equity
- $1.2B
Cash flow
- Operating cash flow
- $200.9M
- Investing cash flow
- -$58.4M
- Financing cash flow
- $8.7M
- Net cash flow
- $151.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $8.9B
- P/E ratio
- 44.1
- EPS (diluted)
- $6.84
- Shares outstanding
- 29.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 20, 2017
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $204.8M in FY2025.
- Trading 5% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 44.1.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Krystal Biotech, Inc..
Write a review
News about Krystal Biotech, Inc.
News & sentiment via Polygon.io
